{"id":7026,"date":"2025-02-25T10:26:07","date_gmt":"2025-02-25T10:26:07","guid":{"rendered":"https:\/\/www.viamedsalud.com\/ivoqa\/?p=7026"},"modified":"2025-02-25T10:26:09","modified_gmt":"2025-02-25T10:26:09","slug":"international-colorectal-disease-symposium","status":"publish","type":"post","link":"https:\/\/www.viamedsalud.com\/ivoqa\/en\/scientific-activity\/international-colorectal-disease-symposium\/","title":{"rendered":"International Colorectal Disease Symposium"},"content":{"rendered":"

The International Symposium on Colorectal Diseases <\/a><\/u>has established itself as the most important annual postgraduate event in the world in the field of colorectal diseases. This symposium brings together an interdisciplinary panel of experts, including colorectal surgeons, gastroenterologists, medical oncologists, pathologists and other specialists, promoting a multidisciplinary approach to innovation for the evaluation and management of pathologies of the colon, rectum, anus and small intestine.<\/p>\n

Dr Delia Cort\u00e9s Guiral, director of IVOQA<\/a>, took part in this annual event, presenting advances and treatment options for colorectal peritoneal metastases using PIPAC (<\/strong>Pressurised Intraperitoneal Aerosol Chemotherapy)<\/a> and HIPEC (<\/strong>Hyperthermic Intraperitoneal Chemotherapy)<\/a>.<\/p>\n

In her first talk, Dr Cort\u00e9s Guiral explained that PIPAC<\/strong> is a therapeutic option for patients with colorectal peritoneal metastases with a Peritoneal Cancer Index (PCI)<\/a> >16<\/strong>\u00a0or unresectable disease, such as in cases of extensive involvement of the small intestine, which progress to second-line systemic therapy, similar to that performed in IVOQA.<\/p>\n

In his second talk, he addressed the role of hyperthermic intraperitoneal chemotherapy<\/strong>\u00a0(HIPEC) in the treatment of colorectal peritoneal metastasis. He concluded that the role of HIPEC in this context has yet to be elucidated, although the current consensus suggests that mitomycin HIPEC<\/strong>\u00a0can be proposed to patients with a pCCI <17<\/strong>\u00a0and when complete cytoreductive surgery can be achieved, either by open or laparoscopic approach.<\/p>\n